Verona Pharma plc
Verona Pharma plc VRNA Peers
See (VRNA) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| VRNA | $104.86 | +0.08% | 8.9B | -52.42 | -$2.00 | N/A |
| VRTX | $470.41 | -1.79% | 123.2B | -125.89 | -$3.81 | N/A |
| REGN | $563.67 | +2.01% | 59.4B | 14.22 | $39.36 | +0.31% |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $315.93 | -1.54% | 42.1B | -153.69 | -$2.10 | N/A |
| ARGX | $561.57 | +1.15% | 34.4B | 34.37 | $16.39 | N/A |
| BNTX | $112.75 | +0.87% | 27.4B | -30.31 | -$3.76 | N/A |
| RPRX | $35.83 | -0.13% | 20.3B | 14.74 | $2.45 | +2.95% |
| BGNE | $184.71 | +0.49% | 20.2B | -22.55 | -$8.19 | N/A |
| SMMT | $25.09 | +1.41% | 19.2B | -76.19 | -$0.34 | N/A |
Stock Comparison
VRNA vs VRTX Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, VRTX has a market cap of 123.2B. Regarding current trading prices, VRNA is priced at $104.86, while VRTX trades at $470.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas VRTX's P/E ratio is -125.89. In terms of profitability, VRNA's ROE is -0.90%, compared to VRTX's ROE of -0.06%. Regarding short-term risk, VRNA is less volatile compared to VRTX. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs REGN Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, REGN has a market cap of 59.4B. Regarding current trading prices, VRNA is priced at $104.86, while REGN trades at $563.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas REGN's P/E ratio is 14.22. In terms of profitability, VRNA's ROE is -0.90%, compared to REGN's ROE of +0.15%. Regarding short-term risk, VRNA is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs SGEN Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, VRNA is priced at $104.86, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas SGEN's P/E ratio is -57.19. In terms of profitability, VRNA's ROE is -0.90%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, VRNA is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for VRNA.
VRNA vs ALNY Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, ALNY has a market cap of 42.1B. Regarding current trading prices, VRNA is priced at $104.86, while ALNY trades at $315.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas ALNY's P/E ratio is -153.69. In terms of profitability, VRNA's ROE is -0.90%, compared to ALNY's ROE of -5.09%. Regarding short-term risk, VRNA is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs ARGX Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, ARGX has a market cap of 34.4B. Regarding current trading prices, VRNA is priced at $104.86, while ARGX trades at $561.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas ARGX's P/E ratio is 34.37. In terms of profitability, VRNA's ROE is -0.90%, compared to ARGX's ROE of +0.23%. Regarding short-term risk, VRNA is less volatile compared to ARGX. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs BNTX Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, BNTX has a market cap of 27.4B. Regarding current trading prices, VRNA is priced at $104.86, while BNTX trades at $112.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas BNTX's P/E ratio is -30.31. In terms of profitability, VRNA's ROE is -0.90%, compared to BNTX's ROE of -0.04%. Regarding short-term risk, VRNA is less volatile compared to BNTX. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs RPRX Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, RPRX has a market cap of 20.3B. Regarding current trading prices, VRNA is priced at $104.86, while RPRX trades at $35.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas RPRX's P/E ratio is 14.74. In terms of profitability, VRNA's ROE is -0.90%, compared to RPRX's ROE of +0.16%. Regarding short-term risk, VRNA is less volatile compared to RPRX. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs BGNE Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, VRNA is priced at $104.86, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas BGNE's P/E ratio is -22.55. In terms of profitability, VRNA's ROE is -0.90%, compared to BGNE's ROE of -0.12%. Regarding short-term risk, VRNA is less volatile compared to BGNE. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs SMMT Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, SMMT has a market cap of 19.2B. Regarding current trading prices, VRNA is priced at $104.86, while SMMT trades at $25.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas SMMT's P/E ratio is -76.19. In terms of profitability, VRNA's ROE is -0.90%, compared to SMMT's ROE of -0.70%. Regarding short-term risk, VRNA is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs DNA-WT Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, VRNA is priced at $104.86, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, VRNA's ROE is -0.90%, compared to DNA-WT's ROE of -0.63%. Regarding short-term risk, VRNA is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs INCY Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, INCY has a market cap of 13.6B. Regarding current trading prices, VRNA is priced at $104.86, while INCY trades at $69.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas INCY's P/E ratio is 351.65. In terms of profitability, VRNA's ROE is -0.90%, compared to INCY's ROE of +0.01%. Regarding short-term risk, VRNA is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs UTHR Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, UTHR has a market cap of 13.5B. Regarding current trading prices, VRNA is priced at $104.86, while UTHR trades at $297.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas UTHR's P/E ratio is 11.96. In terms of profitability, VRNA's ROE is -0.90%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, VRNA is less volatile compared to UTHR. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs GMAB Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, GMAB has a market cap of 13.5B. Regarding current trading prices, VRNA is priced at $104.86, while GMAB trades at $21.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas GMAB's P/E ratio is 12.86. In terms of profitability, VRNA's ROE is -0.90%, compared to GMAB's ROE of +0.26%. Regarding short-term risk, VRNA is less volatile compared to GMAB. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs MRNA Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, MRNA has a market cap of 13.3B. Regarding current trading prices, VRNA is priced at $104.86, while MRNA trades at $33.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas MRNA's P/E ratio is -3.93. In terms of profitability, VRNA's ROE is -0.90%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, VRNA is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs KRTX Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, VRNA is priced at $104.86, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas KRTX's P/E ratio is -28.09. In terms of profitability, VRNA's ROE is -0.90%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, VRNA is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for VRNA.
VRNA vs EXEL Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, EXEL has a market cap of 12.3B. Regarding current trading prices, VRNA is priced at $104.86, while EXEL trades at $45.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas EXEL's P/E ratio is 20.62. In terms of profitability, VRNA's ROE is -0.90%, compared to EXEL's ROE of +0.29%. Regarding short-term risk, VRNA is less volatile compared to EXEL. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs BMRN Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, BMRN has a market cap of 11.3B. Regarding current trading prices, VRNA is priced at $104.86, while BMRN trades at $58.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas BMRN's P/E ratio is 21.79. In terms of profitability, VRNA's ROE is -0.90%, compared to BMRN's ROE of +0.09%. Regarding short-term risk, VRNA is less volatile compared to BMRN. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs ASND Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, ASND has a market cap of 10.6B. Regarding current trading prices, VRNA is priced at $104.86, while ASND trades at $175.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas ASND's P/E ratio is -25.79. In terms of profitability, VRNA's ROE is -0.90%, compared to ASND's ROE of +1.91%. Regarding short-term risk, VRNA is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs RXDX Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, VRNA is priced at $104.86, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas RXDX's P/E ratio is -56.47. In terms of profitability, VRNA's ROE is -0.90%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, VRNA is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for VRNA.
VRNA vs BBIO Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, BBIO has a market cap of 8.8B. Regarding current trading prices, VRNA is priced at $104.86, while BBIO trades at $46.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas BBIO's P/E ratio is -13.00. In terms of profitability, VRNA's ROE is -0.90%, compared to BBIO's ROE of +0.49%. Regarding short-term risk, VRNA is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs IMGN Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, VRNA is priced at $104.86, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas IMGN's P/E ratio is -111.55. In terms of profitability, VRNA's ROE is -0.90%, compared to IMGN's ROE of -1.43%. Regarding short-term risk, VRNA is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for VRNA.
VRNA vs TECH Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, TECH has a market cap of 8.5B. Regarding current trading prices, VRNA is priced at $104.86, while TECH trades at $53.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas TECH's P/E ratio is 65.55. In terms of profitability, VRNA's ROE is -0.90%, compared to TECH's ROE of +0.06%. Regarding short-term risk, VRNA is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs BPMC Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, VRNA is priced at $104.86, while BPMC trades at $129.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas BPMC's P/E ratio is -51.73. In terms of profitability, VRNA's ROE is -0.90%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, VRNA is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for VRNA.
VRNA vs CERE Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, VRNA is priced at $104.86, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas CERE's P/E ratio is -16.47. In terms of profitability, VRNA's ROE is -0.90%, compared to CERE's ROE of -0.43%. Regarding short-term risk, VRNA is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for VRNA.
VRNA vs ROIV Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, ROIV has a market cap of 7.9B. Regarding current trading prices, VRNA is priced at $104.86, while ROIV trades at $11.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas ROIV's P/E ratio is -15.42. In terms of profitability, VRNA's ROE is -0.90%, compared to ROIV's ROE of -0.03%. Regarding short-term risk, VRNA is less volatile compared to ROIV. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs ROIVW Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, VRNA is priced at $104.86, while ROIVW trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, VRNA's ROE is -0.90%, compared to ROIVW's ROE of -0.03%. Regarding short-term risk, VRNA is less volatile compared to ROIVW. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs CORT Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, CORT has a market cap of 7.6B. Regarding current trading prices, VRNA is priced at $104.86, while CORT trades at $71.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas CORT's P/E ratio is 62.67. In terms of profitability, VRNA's ROE is -0.90%, compared to CORT's ROE of +0.20%. Regarding short-term risk, VRNA is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs RVMD Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, RVMD has a market cap of 7.2B. Regarding current trading prices, VRNA is priced at $104.86, while RVMD trades at $38.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas RVMD's P/E ratio is -9.60. In terms of profitability, VRNA's ROE is -0.90%, compared to RVMD's ROE of -0.37%. Regarding short-term risk, VRNA is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs AMRN Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, AMRN has a market cap of 7.1B. Regarding current trading prices, VRNA is priced at $104.86, while AMRN trades at $16.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas AMRN's P/E ratio is -3.92. In terms of profitability, VRNA's ROE is -0.90%, compared to AMRN's ROE of -0.17%. Regarding short-term risk, VRNA is less volatile compared to AMRN. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs HALO Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, HALO has a market cap of 7.1B. Regarding current trading prices, VRNA is priced at $104.86, while HALO trades at $57.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas HALO's P/E ratio is 15.33. In terms of profitability, VRNA's ROE is -0.90%, compared to HALO's ROE of +1.22%. Regarding short-term risk, VRNA is less volatile compared to HALO. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs MDGL Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, MDGL has a market cap of 7B. Regarding current trading prices, VRNA is priced at $104.86, while MDGL trades at $314.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas MDGL's P/E ratio is -17.65. In terms of profitability, VRNA's ROE is -0.90%, compared to MDGL's ROE of -0.51%. Regarding short-term risk, VRNA is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs JAZZ Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, JAZZ has a market cap of 6.8B. Regarding current trading prices, VRNA is priced at $104.86, while JAZZ trades at $110.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas JAZZ's P/E ratio is 15.28. In terms of profitability, VRNA's ROE is -0.90%, compared to JAZZ's ROE of +0.12%. Regarding short-term risk, VRNA is less volatile compared to JAZZ. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs IONS Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, IONS has a market cap of 6.7B. Regarding current trading prices, VRNA is priced at $104.86, while IONS trades at $41.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas IONS's P/E ratio is -14.18. In terms of profitability, VRNA's ROE is -0.90%, compared to IONS's ROE of -0.92%. Regarding short-term risk, VRNA is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs RETA Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, VRNA is priced at $104.86, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas RETA's P/E ratio is -66.29. In terms of profitability, VRNA's ROE is -0.90%, compared to RETA's ROE of +0.47%. Regarding short-term risk, VRNA is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for VRNA.
VRNA vs TGTX Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, TGTX has a market cap of 6B. Regarding current trading prices, VRNA is priced at $104.86, while TGTX trades at $37.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas TGTX's P/E ratio is 150.68. In terms of profitability, VRNA's ROE is -0.90%, compared to TGTX's ROE of +0.19%. Regarding short-term risk, VRNA is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs RYTM Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, RYTM has a market cap of 5.7B. Regarding current trading prices, VRNA is priced at $104.86, while RYTM trades at $87.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas RYTM's P/E ratio is -31.82. In terms of profitability, VRNA's ROE is -0.90%, compared to RYTM's ROE of -1.80%. Regarding short-term risk, VRNA is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs ABCM Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, VRNA is priced at $104.86, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, VRNA's ROE is -0.90%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, VRNA is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for VRNA.
VRNA vs ISEE Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, VRNA is priced at $104.86, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas ISEE's P/E ratio is -22.44. In terms of profitability, VRNA's ROE is -0.90%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, VRNA is less volatile compared to ISEE. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs AXSM Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, AXSM has a market cap of 5.4B. Regarding current trading prices, VRNA is priced at $104.86, while AXSM trades at $109.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas AXSM's P/E ratio is -18.82. In terms of profitability, VRNA's ROE is -0.90%, compared to AXSM's ROE of -3.64%. Regarding short-term risk, VRNA is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs NUVL Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, NUVL has a market cap of 5.4B. Regarding current trading prices, VRNA is priced at $104.86, while NUVL trades at $81.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas NUVL's P/E ratio is -18.57. In terms of profitability, VRNA's ROE is -0.90%, compared to NUVL's ROE of -0.31%. Regarding short-term risk, VRNA is less volatile compared to NUVL. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs TLX Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, TLX has a market cap of 5.4B. Regarding current trading prices, VRNA is priced at $104.86, while TLX trades at $15.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas TLX's P/E ratio is 178.44. In terms of profitability, VRNA's ROE is -0.90%, compared to TLX's ROE of +0.14%. Regarding short-term risk, VRNA is less volatile compared to TLX. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs CRSP Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, CRSP has a market cap of 5.1B. Regarding current trading prices, VRNA is priced at $104.86, while CRSP trades at $56.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas CRSP's P/E ratio is -13.14. In terms of profitability, VRNA's ROE is -0.90%, compared to CRSP's ROE of -0.20%. Regarding short-term risk, VRNA is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs ALKS Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, ALKS has a market cap of 5B. Regarding current trading prices, VRNA is priced at $104.86, while ALKS trades at $30.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas ALKS's P/E ratio is 14.51. In terms of profitability, VRNA's ROE is -0.90%, compared to ALKS's ROE of +0.25%. Regarding short-term risk, VRNA is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs PCVX Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, PCVX has a market cap of 4.7B. Regarding current trading prices, VRNA is priced at $104.86, while PCVX trades at $35.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas PCVX's P/E ratio is -9.09. In terms of profitability, VRNA's ROE is -0.90%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, VRNA is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs ALPN Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, VRNA is priced at $104.86, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas ALPN's P/E ratio is -101.52. In terms of profitability, VRNA's ROE is -0.90%, compared to ALPN's ROE of -0.04%. Regarding short-term risk, VRNA is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for VRNA.
VRNA vs ADMA Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, ADMA has a market cap of 4.4B. Regarding current trading prices, VRNA is priced at $104.86, while ADMA trades at $18.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas ADMA's P/E ratio is 21.99. In terms of profitability, VRNA's ROE is -0.90%, compared to ADMA's ROE of +0.72%. Regarding short-term risk, VRNA is less volatile compared to ADMA. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs CYTK Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, CYTK has a market cap of 4.4B. Regarding current trading prices, VRNA is priced at $104.86, while CYTK trades at $36.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas CYTK's P/E ratio is -6.91. In terms of profitability, VRNA's ROE is -0.90%, compared to CYTK's ROE of +8.01%. Regarding short-term risk, VRNA is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs KRYS Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, KRYS has a market cap of 4.3B. Regarding current trading prices, VRNA is priced at $104.86, while KRYS trades at $148.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas KRYS's P/E ratio is 36.03. In terms of profitability, VRNA's ROE is -0.90%, compared to KRYS's ROE of +0.14%. Regarding short-term risk, VRNA is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs OPT Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, VRNA is priced at $104.86, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas OPT's P/E ratio is -1.52. In terms of profitability, VRNA's ROE is -0.90%, compared to OPT's ROE of +2.60%. Regarding short-term risk, VRNA is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for VRNA.
VRNA vs AKRO Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, AKRO has a market cap of 4.1B. Regarding current trading prices, VRNA is priced at $104.86, while AKRO trades at $51.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas AKRO's P/E ratio is -13.86. In terms of profitability, VRNA's ROE is -0.90%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, VRNA is less volatile compared to AKRO. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs MRTX Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, VRNA is priced at $104.86, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas MRTX's P/E ratio is -4.82. In terms of profitability, VRNA's ROE is -0.90%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, VRNA is less volatile compared to MRTX. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs MRUS Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, MRUS has a market cap of 4.1B. Regarding current trading prices, VRNA is priced at $104.86, while MRUS trades at $54.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas MRUS's P/E ratio is -13.25. In terms of profitability, VRNA's ROE is -0.90%, compared to MRUS's ROE of -0.41%. Regarding short-term risk, VRNA is less volatile compared to MRUS. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs SLNO Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, SLNO has a market cap of 4B. Regarding current trading prices, VRNA is priced at $104.86, while SLNO trades at $82.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas SLNO's P/E ratio is -16.94. In terms of profitability, VRNA's ROE is -0.90%, compared to SLNO's ROE of -0.78%. Regarding short-term risk, VRNA is less volatile compared to SLNO. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs PTCT Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, PTCT has a market cap of 3.9B. Regarding current trading prices, VRNA is priced at $104.86, while PTCT trades at $48.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas PTCT's P/E ratio is 7.61. In terms of profitability, VRNA's ROE is -0.90%, compared to PTCT's ROE of -0.72%. Regarding short-term risk, VRNA is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs MTSR Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, MTSR has a market cap of 3.8B. Regarding current trading prices, VRNA is priced at $104.86, while MTSR trades at $38.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas MTSR's P/E ratio is -14.34. In terms of profitability, VRNA's ROE is -0.90%, compared to MTSR's ROE of -0.63%. Regarding short-term risk, VRNA is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs ACLX Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, ACLX has a market cap of 3.8B. Regarding current trading prices, VRNA is priced at $104.86, while ACLX trades at $68.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas ACLX's P/E ratio is -23.05. In terms of profitability, VRNA's ROE is -0.90%, compared to ACLX's ROE of -0.35%. Regarding short-term risk, VRNA is less volatile compared to ACLX. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs RNA Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, RNA has a market cap of 3.8B. Regarding current trading prices, VRNA is priced at $104.86, while RNA trades at $31.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas RNA's P/E ratio is -10.49. In terms of profitability, VRNA's ROE is -0.90%, compared to RNA's ROE of -0.27%. Regarding short-term risk, VRNA is less volatile compared to RNA. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs ZLAB Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, ZLAB has a market cap of 3.8B. Regarding current trading prices, VRNA is priced at $104.86, while ZLAB trades at $32.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas ZLAB's P/E ratio is -13.62. In terms of profitability, VRNA's ROE is -0.90%, compared to ZLAB's ROE of -0.33%. Regarding short-term risk, VRNA is less volatile compared to ZLAB. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs RYZB Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, VRNA is priced at $104.86, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas RYZB's P/E ratio is -57.86. In terms of profitability, VRNA's ROE is -0.90%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, VRNA is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for VRNA.
VRNA vs CBAY Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, VRNA is priced at $104.86, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas CBAY's P/E ratio is -32.81. In terms of profitability, VRNA's ROE is -0.90%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, VRNA is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for VRNA.
VRNA vs ACAD Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, ACAD has a market cap of 3.7B. Regarding current trading prices, VRNA is priced at $104.86, while ACAD trades at $21.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas ACAD's P/E ratio is 16.10. In terms of profitability, VRNA's ROE is -0.90%, compared to ACAD's ROE of +0.35%. Regarding short-term risk, VRNA is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs LEGN Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, LEGN has a market cap of 3.7B. Regarding current trading prices, VRNA is priced at $104.86, while LEGN trades at $39.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas LEGN's P/E ratio is -33.66. In terms of profitability, VRNA's ROE is -0.90%, compared to LEGN's ROE of -0.20%. Regarding short-term risk, VRNA is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs SRRK Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, SRRK has a market cap of 3.6B. Regarding current trading prices, VRNA is priced at $104.86, while SRRK trades at $37.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas SRRK's P/E ratio is -14.95. In terms of profitability, VRNA's ROE is -0.90%, compared to SRRK's ROE of -1.18%. Regarding short-term risk, VRNA is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs AAPG Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, AAPG has a market cap of 3.5B. Regarding current trading prices, VRNA is priced at $104.86, while AAPG trades at $38.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas AAPG's P/E ratio is -54.43. In terms of profitability, VRNA's ROE is -0.90%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, VRNA is less volatile compared to AAPG. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs SWTX Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, VRNA is priced at $104.86, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas SWTX's P/E ratio is -13.78. In terms of profitability, VRNA's ROE is -0.90%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, VRNA is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for VRNA.
VRNA vs VKTX Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, VKTX has a market cap of 3.5B. Regarding current trading prices, VRNA is priced at $104.86, while VKTX trades at $30.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas VKTX's P/E ratio is -26.97. In terms of profitability, VRNA's ROE is -0.90%, compared to VKTX's ROE of -0.14%. Regarding short-term risk, VRNA is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs PTGX Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, PTGX has a market cap of 3.3B. Regarding current trading prices, VRNA is priced at $104.86, while PTGX trades at $53.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas PTGX's P/E ratio is 67.77. In terms of profitability, VRNA's ROE is -0.90%, compared to PTGX's ROE of +0.09%. Regarding short-term risk, VRNA is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs KYMR Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, KYMR has a market cap of 3.2B. Regarding current trading prices, VRNA is priced at $104.86, while KYMR trades at $44.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas KYMR's P/E ratio is -14.52. In terms of profitability, VRNA's ROE is -0.90%, compared to KYMR's ROE of -0.30%. Regarding short-term risk, VRNA is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs MLTX Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, MLTX has a market cap of 3.1B. Regarding current trading prices, VRNA is priced at $104.86, while MLTX trades at $49.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas MLTX's P/E ratio is -21.29. In terms of profitability, VRNA's ROE is -0.90%, compared to MLTX's ROE of -0.31%. Regarding short-term risk, VRNA is less volatile compared to MLTX. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs CRNX Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, CRNX has a market cap of 3B. Regarding current trading prices, VRNA is priced at $104.86, while CRNX trades at $31.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas CRNX's P/E ratio is -8.42. In terms of profitability, VRNA's ROE is -0.90%, compared to CRNX's ROE of -0.31%. Regarding short-term risk, VRNA is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs IMVT Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, IMVT has a market cap of 3B. Regarding current trading prices, VRNA is priced at $104.86, while IMVT trades at $17.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas IMVT's P/E ratio is -6.41. In terms of profitability, VRNA's ROE is -0.90%, compared to IMVT's ROE of -0.81%. Regarding short-term risk, VRNA is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs RARE Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, RARE has a market cap of 2.9B. Regarding current trading prices, VRNA is priced at $104.86, while RARE trades at $29.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas RARE's P/E ratio is -5.32. In terms of profitability, VRNA's ROE is -0.90%, compared to RARE's ROE of -1.86%. Regarding short-term risk, VRNA is less volatile compared to RARE. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs NAMSW Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, NAMSW has a market cap of 2.9B. Regarding current trading prices, VRNA is priced at $104.86, while NAMSW trades at $10.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas NAMSW's P/E ratio is N/A. In terms of profitability, VRNA's ROE is -0.90%, compared to NAMSW's ROE of -0.33%. Regarding short-term risk, VRNA is less volatile compared to NAMSW. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs MORF Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, VRNA is priced at $104.86, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas MORF's P/E ratio is -14.88. In terms of profitability, VRNA's ROE is -0.90%, compared to MORF's ROE of -0.22%. Regarding short-term risk, VRNA is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for VRNA.
VRNA vs MOR Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, VRNA is priced at $104.86, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas MOR's P/E ratio is -12.64. In terms of profitability, VRNA's ROE is -0.90%, compared to MOR's ROE of -1.84%. Regarding short-term risk, VRNA is less volatile compared to MOR. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs KDNY Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, VRNA is priced at $104.86, while KDNY trades at $40.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas KDNY's P/E ratio is -12.47. In terms of profitability, VRNA's ROE is -0.90%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, VRNA is less volatile compared to KDNY. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs CPRX Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, CPRX has a market cap of 2.7B. Regarding current trading prices, VRNA is priced at $104.86, while CPRX trades at $21.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas CPRX's P/E ratio is 13.91. In terms of profitability, VRNA's ROE is -0.90%, compared to CPRX's ROE of +0.28%. Regarding short-term risk, VRNA is less volatile compared to CPRX. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs MYOV Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, VRNA is priced at $104.86, while MYOV trades at $26.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas MYOV's P/E ratio is -14.05. In terms of profitability, VRNA's ROE is -0.90%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, VRNA is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for VRNA.
VRNA vs MIRM Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, MIRM has a market cap of 2.6B. Regarding current trading prices, VRNA is priced at $104.86, while MIRM trades at $53.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas MIRM's P/E ratio is -32.90. In terms of profitability, VRNA's ROE is -0.90%, compared to MIRM's ROE of -0.34%. Regarding short-term risk, VRNA is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs ARWR Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, ARWR has a market cap of 2.6B. Regarding current trading prices, VRNA is priced at $104.86, while ARWR trades at $18.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas ARWR's P/E ratio is -15.22. In terms of profitability, VRNA's ROE is -0.90%, compared to ARWR's ROE of -0.47%. Regarding short-term risk, VRNA is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs IBRX Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, IBRX has a market cap of 2.5B. Regarding current trading prices, VRNA is priced at $104.86, while IBRX trades at $2.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas IBRX's P/E ratio is -5.05. In terms of profitability, VRNA's ROE is -0.90%, compared to IBRX's ROE of +0.65%. Regarding short-term risk, VRNA is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs XENE Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, XENE has a market cap of 2.5B. Regarding current trading prices, VRNA is priced at $104.86, while XENE trades at $32.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas XENE's P/E ratio is -10.24. In terms of profitability, VRNA's ROE is -0.90%, compared to XENE's ROE of -0.32%. Regarding short-term risk, VRNA is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs NAMS Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, NAMS has a market cap of 2.5B. Regarding current trading prices, VRNA is priced at $104.86, while NAMS trades at $21.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas NAMS's P/E ratio is -11.96. In terms of profitability, VRNA's ROE is -0.90%, compared to NAMS's ROE of -0.33%. Regarding short-term risk, VRNA is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs APLS Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, APLS has a market cap of 2.5B. Regarding current trading prices, VRNA is priced at $104.86, while APLS trades at $19.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas APLS's P/E ratio is -10.84. In terms of profitability, VRNA's ROE is -0.90%, compared to APLS's ROE of -1.00%. Regarding short-term risk, VRNA is less volatile compared to APLS. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs LGND Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, LGND has a market cap of 2.4B. Regarding current trading prices, VRNA is priced at $104.86, while LGND trades at $120.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas LGND's P/E ratio is -17.14. In terms of profitability, VRNA's ROE is -0.90%, compared to LGND's ROE of -0.16%. Regarding short-term risk, VRNA is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs PRVB Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, VRNA is priced at $104.86, while PRVB trades at $24.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas PRVB's P/E ratio is -16.43. In terms of profitability, VRNA's ROE is -0.90%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, VRNA is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for VRNA.
VRNA vs LBPH Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, VRNA is priced at $104.86, while LBPH trades at $59.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas LBPH's P/E ratio is -26.66. In terms of profitability, VRNA's ROE is -0.90%, compared to LBPH's ROE of -0.33%. Regarding short-term risk, VRNA is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for VRNA.
VRNA vs APGE Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, APGE has a market cap of 2.3B. Regarding current trading prices, VRNA is priced at $104.86, while APGE trades at $38.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas APGE's P/E ratio is -10.67. In terms of profitability, VRNA's ROE is -0.90%, compared to APGE's ROE of -0.19%. Regarding short-term risk, VRNA is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs AGIO Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, AGIO has a market cap of 2.3B. Regarding current trading prices, VRNA is priced at $104.86, while AGIO trades at $39.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas AGIO's P/E ratio is 3.43. In terms of profitability, VRNA's ROE is -0.90%, compared to AGIO's ROE of +0.50%. Regarding short-term risk, VRNA is less volatile compared to AGIO. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs RXRX Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, RXRX has a market cap of 2.3B. Regarding current trading prices, VRNA is priced at $104.86, while RXRX trades at $5.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas RXRX's P/E ratio is -3.40. In terms of profitability, VRNA's ROE is -0.90%, compared to RXRX's ROE of -0.75%. Regarding short-term risk, VRNA is less volatile compared to RXRX. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs DICE Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, VRNA is priced at $104.86, while DICE trades at $47.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas DICE's P/E ratio is -21.91. In terms of profitability, VRNA's ROE is -0.90%, compared to DICE's ROE of +0.56%. Regarding short-term risk, VRNA is less volatile compared to DICE. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs DNLI Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, DNLI has a market cap of 2.2B. Regarding current trading prices, VRNA is priced at $104.86, while DNLI trades at $14.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas DNLI's P/E ratio is -5.75. In terms of profitability, VRNA's ROE is -0.90%, compared to DNLI's ROE of -0.36%. Regarding short-term risk, VRNA is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs BEAM Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, BEAM has a market cap of 2.2B. Regarding current trading prices, VRNA is priced at $104.86, while BEAM trades at $21.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas BEAM's P/E ratio is -4.78. In terms of profitability, VRNA's ROE is -0.90%, compared to BEAM's ROE of -0.44%. Regarding short-term risk, VRNA is less volatile compared to BEAM. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs VCYT Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, VCYT has a market cap of 2.2B. Regarding current trading prices, VRNA is priced at $104.86, while VCYT trades at $27.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas VCYT's P/E ratio is 65.52. In terms of profitability, VRNA's ROE is -0.90%, compared to VCYT's ROE of +0.03%. Regarding short-term risk, VRNA is less volatile compared to VCYT. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs CALT Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, CALT has a market cap of 2.1B. Regarding current trading prices, VRNA is priced at $104.86, while CALT trades at $40.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas CALT's P/E ratio is -22.73. In terms of profitability, VRNA's ROE is -0.90%, compared to CALT's ROE of -1.67%. Regarding short-term risk, VRNA is less volatile compared to CALT. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs KNSA Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, KNSA has a market cap of 2.1B. Regarding current trading prices, VRNA is priced at $104.86, while KNSA trades at $27.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas KNSA's P/E ratio is -120.58. In terms of profitability, VRNA's ROE is -0.90%, compared to KNSA's ROE of -0.04%. Regarding short-term risk, VRNA is less volatile compared to KNSA. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs VCEL Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, VCEL has a market cap of 2.1B. Regarding current trading prices, VRNA is priced at $104.86, while VCEL trades at $40.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas VCEL's P/E ratio is 824.80. In terms of profitability, VRNA's ROE is -0.90%, compared to VCEL's ROE of +0.01%. Regarding short-term risk, VRNA is less volatile compared to VCEL. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs CGON Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, CGON has a market cap of 2.1B. Regarding current trading prices, VRNA is priced at $104.86, while CGON trades at $26.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas CGON's P/E ratio is -18.30. In terms of profitability, VRNA's ROE is -0.90%, compared to CGON's ROE of -0.17%. Regarding short-term risk, VRNA is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.
VRNA vs BLTE Comparison
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, BLTE has a market cap of 2B. Regarding current trading prices, VRNA is priced at $104.86, while BLTE trades at $62.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.42, whereas BLTE's P/E ratio is -45.93. In terms of profitability, VRNA's ROE is -0.90%, compared to BLTE's ROE of -0.32%. Regarding short-term risk, VRNA is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.